Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending March 2011. The report details a specific share repurchase transaction executed on March 18, 2011, pursuant to shareholder authority granted at the Annual General Meeting on May 6, 2010.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. It focuses exclusively on capital structure changes related to share buybacks.
- Shares Purchased: 1,300,000 Ordinary shares of 25 pence each.
- Price Range: Highest price paid was 1,157.5 pence per share; lowest price paid was 1,145 pence per share.
- Treasury Holdings: Following cancellation, the Company holds 493,224,284 shares in Treasury (including unsettled purchases).
- Treasury Percentage: Treasury shares represent 9.52% of total issued share capital and 8.67% of total voting rights.
- Shares in Issue: 5,179,455,625 shares (excluding Treasury shares).
Material Changes
The primary material change is the reduction of outstanding share capital through the purchase and cancellation of 1,300,000 shares. This action increased the proportion of shares held in Treasury to 9.52% of total issued capital.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a compliance disclosure confirming conformity with the Financial Services Authority's Disclosure and Transparency Rules.
Investor Verification Points
- Verify the total number of shares in issue (5,179,455,625) for calculating ownership thresholds under Disclosure and Transparency Rules.
- Confirm the updated Treasury share count (493,224,284) and its impact on voting rights (8.67%).
- Note that the purchased shares were cancelled, permanently reducing the company's share count.